Lanthanum Carbonate: A Review of its Use in Lowering Serum Phosphate in Patients with End-Stage Renal Disease

Authors: Curran, Monique P.; Robinson, Dean M.

Source: Drugs, Volume 69, Number 16, 12 November 2009 , pp. 2329-2349(21)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

Abstract Orally administered lanthanum carbonate (Fosrenol®) dissociates in the acid environment of the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary phosphate.

Lanthanum carbonate was effective in reducing levels of serum phosphate and serum calcium × phosphate product and then maintaining these levels within target ranges for up to 6 years in adult patients with end-stage renal disease (ESRD) on haemodialysis or peritoneal dialysis. The reduction in serum phosphate levels with lanthanum carbonate was generally similar to that with calcium carbonate or sevelamer hydrochloride. This agent was generally well tolerated, with the most frequently reported adverse events being gastrointestinal in nature and occurring at a similar rate to that with calcium carbonate. However, lanthanum carbonate was associated with fewer episodes of hypercalcaemia than calcium carbonate. Overall, lanthanum carbonate is a valuable option for the reduction of serum phosphate levels in patients with ESRD on haemodialysis or peritoneal dialysis.

Document Type: Research article

Affiliations: 1: Adis, a Wolters Kluwer Business, Auckland, New Zealand

Publication date: 2009-11-12